基于固相萃取色谱的放射化学分离富集54Fe靶中回旋产生的51Mn。

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2024-12-17 DOI:10.1016/j.nucmedbio.2024.108989

Kendall E Barrett, Jason C Mixdorf, Johan Svedjehed, Jeanine Batterton, Jennifer Eagleburger, Yongjun Yan, Katherine Gagnon, Eduardo Aluicio-Sarduy, Todd E Barnhart, Jonathan W Engle

{"title":"基于固相萃取色谱的放射化学分离富集54Fe靶中回旋产生的51Mn。","authors":"Kendall E Barrett, Jason C Mixdorf, Johan Svedjehed, Jeanine Batterton, Jennifer Eagleburger, Yongjun Yan, Katherine Gagnon, Eduardo Aluicio-Sarduy, Todd E Barnhart, Jonathan W Engle","doi":"10.1016/j.nucmedbio.2024.108989","DOIUrl":null,"url":null,"abstract":"We report DGA extraction chromatography isolation of 51Mn from isotopically enriched 54Fe. The method has been studied in semi-automated and automated realizations. The former achieves a decay corrected radiochemical yield of 78 ± 1 % (n = 3) and a separation factor of (1.0 ± 0.8) x 105 (n = 3). With GE HealthCare's Solid Target Platform (STP) and FASTlab the latter, fully automated method achieves a decay corrected radiochemical yield of 87 ± 1 % (n = 3) and a separation factor of (2.7 ± 0.9) x 104 (n = 3). Both setups efficiently isolate cyclotron-produced 51MnCl2 suitable for human administration as determined by developed Chemistry, Manufacturing, and Controls (CMC) acceptance criteria, and support exploration of 51Mn as a clinical diagnostic tool.","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"142-143 ","pages":"108989"},"PeriodicalIF":3.6000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Solid phase extraction chromatography-based radiochemical isolation of cyclotron-produced 51Mn from enriched 54Fe targets.\",\"authors\":\"Kendall E Barrett, Jason C Mixdorf, Johan Svedjehed, Jeanine Batterton, Jennifer Eagleburger, Yongjun Yan, Katherine Gagnon, Eduardo Aluicio-Sarduy, Todd E Barnhart, Jonathan W Engle\",\"doi\":\"10.1016/j.nucmedbio.2024.108989\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report DGA extraction chromatography isolation of 51Mn from isotopically enriched 54Fe. The method has been studied in semi-automated and automated realizations. The former achieves a decay corrected radiochemical yield of 78 ± 1 % (n = 3) and a separation factor of (1.0 ± 0.8) x 105 (n = 3). With GE HealthCare's Solid Target Platform (STP) and FASTlab the latter, fully automated method achieves a decay corrected radiochemical yield of 87 ± 1 % (n = 3) and a separation factor of (2.7 ± 0.9) x 104 (n = 3). Both setups efficiently isolate cyclotron-produced 51MnCl2 suitable for human administration as determined by developed Chemistry, Manufacturing, and Controls (CMC) acceptance criteria, and support exploration of 51Mn as a clinical diagnostic tool.\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"142-143 \",\"pages\":\"108989\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.nucmedbio.2024.108989\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.nucmedbio.2024.108989","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

本文报道了从同位素富集的54Fe中分离51Mn的DGA萃取色谱法。该方法已在半自动化和自动化实现中进行了研究。前达到衰减校正放射化学收益率78±1% (n = 3)和分离系数(1.0±0.8)x 105 (n = 3)。与通用电气医疗集团的固体目标平台(STP)和FASTlab后者,完全自动化的方法达到一个衰变校正放射化学收益率87±1% (n = 3)和分离系数(2.7±0.9)x 104 (n = 3),设置有效地隔离cyclotron-produced 51 mncl2适合人类管理由开发化学、制造、并支持51Mn作为临床诊断工具的探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Solid phase extraction chromatography-based radiochemical isolation of cyclotron-produced ⁵¹Mn from enriched ⁵⁴Fe targets.

We report DGA extraction chromatography isolation of ⁵¹Mn from isotopically enriched ⁵⁴Fe. The method has been studied in semi-automated and automated realizations. The former achieves a decay corrected radiochemical yield of 78 ± 1 % (n = 3) and a separation factor of (1.0 ± 0.8) x 10⁵ (n = 3). With GE HealthCare's Solid Target Platform (STP) and FASTlab the latter, fully automated method achieves a decay corrected radiochemical yield of 87 ± 1 % (n = 3) and a separation factor of (2.7 ± 0.9) x 10⁴ (n = 3). Both setups efficiently isolate cyclotron-produced ⁵¹MnCl₂ suitable for human administration as determined by developed Chemistry, Manufacturing, and Controls (CMC) acceptance criteria, and support exploration of ⁵¹Mn as a clinical diagnostic tool.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.